Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future.
about
The Autoimmune EcologyExploring new territory: considering the futureTolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome.Safety and efficacy of combined cyclophosphamide and rituximab treatment in recalcitrant childhood lupus.A novel subset of memory B cells is enriched in autoreactivity and correlates with adverse outcomes in SLEPathogenesis of human systemic lupus erythematosus: recent advances.Targeting B cells with biologics in systemic lupus erythematosus.Rituximab therapy in idiopathic membranous nephropathy: a 2-year study.Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosusB cell depletion enhances T regulatory cell activity essential in the suppression of arthritis.B cells expressing IFN-γ suppress Treg-cell differentiation and promote autoimmune experimental arthritis.Biologic therapies: what and when?Changes in macrophage function after rituximab treatment in patients with rheumatoid arthritis.B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response.Differential cytokine production and bystander activation of autoreactive B cells in response to CpG-A and CpG-B oligonucleotides.Rituximab therapy for juvenile-onset systemic lupus erythematosus.Maintenance of the plasma cell pool is independent of memory B cells.B lymphocytes as therapeutic targets in systemic lupus erythematosus.Regulation of lupus-related autoantibody production and clinical disease by Toll-like receptorsSystemic lupus erythematosus in children: current and emerging therapies.Targeting CD22 reprograms B-cells and reverses autoimmune diabetes.Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study.Targeting of the immune system in systemic lupus erythematosus.Current treatment of lupus nephritis.A new site-directed transgenic rheumatoid factor mouse model demonstrates extrafollicular class switch and plasmablast formationUpdate on the role of rituximab in kidney diseases and transplant.A systematic review of biologics for the treatment of noninfectious uveitis.Pediatric lupus nephritis: more options, more chances?An acquired defect in IgG-dependent phagocytosis explains the impairment in antibody-mediated cellular depletion in Lupus.Insights into the naturally acquired immune response to Plasmodium vivax malaria.Rituximab in the treatment of resistant lupus nephritis: therapy failure in rapidly progressive crescentic lupus nephritis.Rituximab treatment in patients with active Graves' orbitopathy: effects on proinflammatory and humoral immune reactions.The regulation of autoreactive B cells during innate immune responses.IL2/IL21 region polymorphism influences response to rituximab in systemic lupus erythematosus patients.The Function of MicroRNAs in B-Cell Development, Lymphoma, and Their Potential in Clinical Practice.
P2860
Q26747427-8A63EBFA-9535-481C-B22A-E563AF23A7B5Q28222277-86AA59A3-BEDC-4930-96A8-A214F81D87FAQ33372523-2D68D1A5-4FBC-4510-B6DB-407700111EB7Q33411406-2BF2D83E-1D44-4F40-936F-DA01702E4DF3Q33614719-DCE33D80-2C06-4FAB-B3CA-6BA1B089223BQ33664927-82D58E35-02BE-4921-9ED1-0B089E19DE80Q34232326-8809BC59-7964-4007-ABB7-15979231ABD7Q34362660-A8AAD0AE-ABB1-4A8A-AB17-424E854B4036Q34897437-F0245E0A-1FB3-4BB8-9D63-2D59BAF467DFQ35623403-3DB48066-448A-48B3-9F5C-3D232AED2018Q35627016-DECDFB15-B541-4C5F-8A5F-2A59F5955D1EQ35770607-030B6D15-3861-4C3F-89DB-ADB2180C65B7Q35953417-AD0E1260-C401-42F2-9958-31D477A39CA2Q35954653-F80A3F3A-4AC6-49F8-965D-B016329E0EBEQ36186840-F84CCDA8-F8B2-415F-A175-5D5AB6C0546BQ36407310-D1A51779-862E-4263-8DB1-D90294165120Q36534521-7D476B60-22DC-4FA0-ADF9-2BA64C24FCACQ36653646-FFD9FA86-DD3E-46FA-A7E3-7E858108A7EFQ36727307-601549C6-8CE9-40BE-95F9-51C9876FB3C5Q36915688-1974A3C4-F9A3-4571-9439-E76CAD901327Q36943737-2B902D26-2B99-4105-94CD-18ED49AC0E0EQ36975931-C07B815B-A0FE-45E7-AB77-34B15784E760Q37060593-0826CC28-579B-4A5F-A50A-EE140D212D12Q37168027-DA259B9C-5AE4-4C64-8E2A-7EB4E4A20B5CQ37283622-376F1476-0C14-446C-8ACA-A0A34AE92DC3Q37970443-711F04A4-2375-4137-8976-DF72BD1400BAQ38068969-D4830F49-E53B-4C18-BAFC-9855886CF1ACQ38102946-B0CBD9B2-2258-4C2B-BE8B-9EAAD1575B54Q38546315-AA6F524E-81BD-42A7-8960-38F881523348Q38728598-A8654F30-E1D4-4373-BB2D-62A8F0202049Q42597354-5D9F8A4B-A14D-4CE7-9A3B-3DD55FFDFF42Q43042591-36DD6425-03B6-4B32-8546-685B58F19429Q43100973-D7E7F143-9D6B-430F-8962-17F01EEE0B27Q43693855-C0BC1D7B-971E-4EE6-AD10-38DB17BA1A9FQ54211938-82A36ABA-3D6D-4C70-B3C4-EF8EDA7DCD8A
P2860
Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future.
@ast
Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future.
@en
type
label
Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future.
@ast
Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future.
@en
prefLabel
Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future.
@ast
Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future.
@en
P2093
P1476
Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future.
@en
P2093
George C Tsokos
John N Boletis
Petros P Sfikakis
P304
P356
10.1097/01.BOR.0000172798.26249.FC
P577
2005-09-01T00:00:00Z